The Risk/Benefit Profile of Biologic Drugs in Real-World Rheumatology Practice. From ANTARES to MonitorNet

Reumatismo - Italy
doi 10.4081/reumatismo.2008.77
Full Text
Abstract

Available in full text

Categories
Rheumatology
Date
Authors
Publisher

PAGEPress Publications

Related search

THU0503 Cost Analysis of Anti-Osteoporotic Drugs in Real-World Clinical Practice

2018English

5psq-075 Safety Profile of Fingolimod in Real World Clinical Practice: A Preliminary Study

2020English

Evidence-Based Practice in the Real World

Evidence and Policy
Sports MedicineCardiologySocial SciencesOrthopedicsCardiovascular MedicinePhysiology
2005English

Unbalanced Risk-Benefit Analysis of ADHD Drugs

The Lancet Psychiatry
PsychiatryBiological PsychiatryMental Health
2018English

The Wide World of Rheumatology

Wiener Klinische Wochenschrift
Medicine
2016English

Biologic Frontiers in Multiple Myeloma: From Biomarker Identification to Clinical Practice

Clinical Cancer Research
Cancer ResearchOncology
2013English

Changes in Real-World Practice Patterns of Antiepileptic Drugs for Status Epilepticus: A Nationwide Observational Study in Japan

Neurologia Medico-Chirurgica
SurgeryNeurology
2020English

Real-World Effectiveness of Biologic Disease-Modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany

Clinical Therapeutics
Pharmacology
2017English

Characteristics of Patients Starting Biologic Treatments for Rheumatoid Arthritis in the Real World: Systematic Review

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy